PXD-101 |
PX-105684 |
NSC726630 |
BELINOSTAT |
BELEODAQ |
rxcui:1543543 |
chembl:CHEMBL408513 |
pubchem.compound:6918638 |
chemidplus:866323-14-0 |
drugbank:05015 |
FDA Approval | Peripheral T-cell lymphoma |
Drug Class | Small molecule inhibitor |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
Drug Categories | cytochrome p-450 cyp1a2 inducers |
Drug Categories | cytochrome p-450 cyp1a2 inducers (weak) |
Drug Categories | cytochrome p-450 cyp2a6 substrates |
Drug Categories | cytochrome p-450 cyp2a6 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors (weak) |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2c9 substrates |
Drug Categories | cytochrome p-450 cyp2c9 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 enzyme inducers |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | immunosuppressive agents |
Drug Categories | p-glycoprotein substrates |
Drug Categories | ugt1a1 substrates |
Drug Categories | ugt1a1 substrates with narrow therapeutic index |
inhibitor (inhibitory) |
Notes | |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Notes | |
Trial Name | PXD101 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Trial Name | PXD101 |
Novel drug target | Established target |
Notes |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | PXD101 |
Notes |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Trial Name | PXD101 |
Novel drug target | Established target |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Histone deacetylase inhibitor |
Direct Interaction | yes |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Notes | |
Mechanism of Interaction | Histone deacetylase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Histone deacetylase inhibitor |
Trial Name | PXD101 |
inhibitor (inhibitory) |
Notes | |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Notes | |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
BELINOSTAT | DrugBank Drug Name |
866323-14-0 | CAS Number |
Beleodaq | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
BELEODAQ | Trade Name |
Drug Class | Small molecule inhibitor |
FDA Approval | Peripheral T-cell lymphoma |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
CHEMBL408513 | ChEMBL Drug ID |
BELINOSTAT | Primary Drug Name |
BELINOSTAT | Drug Generic Name |
PXD 101 | Drug Synonym |
BELINOSTAT | GuideToPharmacology Ligand Name |